Over 2,000 letters being delivered to Premiers and Health Ministers across Canada urging access to life-extending treatment for PAH
Today, Scleroderma Canada and the Pulmonary Hypertension Association of Canada announced that they have collected over 2,000 signed letters and are in the process of delivering them to Premiers and Health Ministers across Canada, including Manitoba, Ontario, Quebec and Nova Scotia. The letters were signed by individuals living with pulmonary arterial hypertension (PAH), their caregivers, family members and friends to urge decision makers to make …
Actelion Receives FDA Approval Of TRACLEER® (bosentan) For Use In Pediatric Patients With Pulmonary Arterial Hypertension
Actelion Pharmaceuticals US, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that the U.S. Food and Drug Administration (FDA) has approved a new 32 mg tablet for oral suspension for TRACLEER® (bosentan) for use in pediatric patients aged three years and older with idiopathic or congenital pulmonary arterial hypertension (PAH), to improve pulmonary vascular resistance (PVR), which is expected to result in an…
Pulmonary Arterial Hypertension Treatment Gets Expanded FDA Approval
The U.S. Food and Drug Administration (FDA) granted approval to Actelion’s Tracleer (bosentan) tablet for use in pediatric patients ages 3 years and older with idiopathic or congenital pulmonary arterial hypertension (PAH).
Turning lipids research into new drugs
A lipid (fat) whose anti-inflammatory activities were discovered by Cardiff University, with colleagues from Universities of Pittsburgh, Oregon and Michigan, is being developed into a new drug for the treatment of diseases that currently have limited therapeutic options.
Cleveland Clinic Researchers Find Beta Blockers Have Positive Effect in Pulmonary Arterial Hypertension
A team of Cleveland Clinic researchers found that a common heart disease medication, beta blockers, may help treat pulmonary arterial hypertension (PAH), a debilitating lung disease.
Combination of Biomarkers Identified That Predicts Disease Progression in IPH
The ratio between the proteins MMP2 and TIMP4 in blood samples of idiopathic pulmonary arterial hypertension (iPAH) patients was found to predict disease worsening and mortality in a German study.
Holistic Approach Helps Patients Engage in Care
Recent advances and clinical research have shown that better care for people with pulmonary arterial hypertension (PAH) can lead to longer lives. But recently the focus has shifted from treatment options that improve the functional aspects of the disease alone to including care that improves overall quality of life and the ability to perform day-to-day activities. A review published in the European Respiratory Review (…
Adcirca Shown Effective for Pediatric Patients with PAH in Clinical Practice in Japan
Adcirca (tadalafil) showed an acceptable safety profile and effectiveness in a real-world clinical cohort of pediatric patients with pulmonary arterial hypertension (PAH) in Japan.
Doctors Are Doing Inadequate Job of Screening Scleroderma Patients for PAH, Study Concludes
Scientists have long known that people with scleroderma are at increased risk of developing pulmonary arterial hypertension. But many with scleroderma whom doctors suspect of having PAH are not receiving optimal screening for the respiratory condition, a study concludes. Nor are enough scleroderma patients suspected of having pulmonary hypertension being referred for tests that would confirm the condition.
Anges Québec leads $us 9 million financing round for innovative medical technology
Anges Québec announced a major investment in 4C Medical Technologies Inc., a company developing minimally invasive therapies for structural heart disease.
Recent News


Get the latest on PH treatments, community events and more when you subscribe to our newsletter